Arthrosi Therapeutics, Inc., founded in San Diego, CA in 2018 with a mission to create a revolutionary treatment option to target uric acid levels and reduce joint damage, while improving quality of life for people living with gout. With its extensive therapeutic and treatment knowledge, Arthrosi has developed an industry leading, safe, and potent selective URAT1 inhibitor that has completed Phase 1, Phase 2a and 2b studies, and currently enrolling a Phase 2 (clinically) tophaceous gout study.